At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 431 enrolled
Drug / intervention
Topical analgesic +2 moredrug
Likely dose
oral intake 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.
In Brief
A Phase 3 clinical trial evaluating Topical analgesic and oral intake for Neuropathic Pain. Completed, enrolled 431 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate lidocaine as topical treatment for peripheral neuropathic pain (as stand-alone treatment and in combination with systemic treatment)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionJan 2008
Study CompletionMar 2008
TodayJul 2026
First PostedDec 21, 2006
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.5 years ago
Interventions
Topical analgesicdrug
max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
oral intakedrug
300 to 600 mg per day taken orally
Topical analgesicdrug
3 plasters for PHN patients per day 4 plasters for DPN patients per day